Neuroscience
From Bloomberg via the New York Times:
-
Anthony H. Risser | neuroscience | neuropsychology | brain
- Business World: Biogen Idec, Elan, & Tysabri (natalizumab) And Ms
From the FDA: FOR IMMEDIATE RELEASE P06-25 February 16, 2006 Media Inquiries: Susan Cruzan, 301-827-6242 Consumer Inquiries: 888-INFO-FDA FDA Allows Clinical Studies of Tysabri (natalizumab) for Treatment of MS to Proceed The Food and...
- Business World: Biogen Idec, Elan, & Tysabri (natalizumab)
From the AP: Elan Shares Jump As Tysabri to Get Review By THE ASSOCIATED PRESS Published: November 18, 2005 Filed at 12:52 p.m. ET DUBLIN, Ireland (AP) -- Shares in Irish drug maker Elan Corp. PLC jumped Friday...
- Business World: Biogen Idec, Elan, & Tysabri (natalizumab) And Avonex (interferon Beta-1a)
From: RTE Ireland:Elan releases Tysabri trial figures July 19, 2005 11:09 Pharmaceutical company Elan has released figures showing that its suspended Tysabri drug improved the effectiveness of Biogen's Avonex in the treatment of multiple sclerosis....
- Business World: Biogen Idec, Elan, & Tysabri (natalizumab) (cont.)
Additional information in follow-up to this morning's Boston Globe report, from Bloomberg:Elan, Biogen Decline on Report of New Tysabri Illness June 2 (Bloomberg) -- Shares of Elan Corp. and Biogen Idec Inc. tumbled after a fourth possible case of...
- More M.s. Drug Woes: Avonex And 683699
Biogen and F.D.A. Issue Drug Warning By ANDREW POLLACK The New York Times Published: March 17, 2005 Biogen Idec's multiple sclerosis drug Avonex might cause severe liver damage in rare cases, the company and the Food and Drug Administration said...
Neuroscience
Business World: Biogen Idec, Elan, Tysabri (Natalizumab), and Multiple Sclerosis
From Bloomberg via the New York Times:
Move to Reinstate Multiple Sclerosis Drug
Published: September 21, 2005
By Bloomberg News
Biogen Idec Inc. and the Elan Corporation said yesterday that they would seek federal regulatory approval to resume sales of the withdrawn Tysabri drug for multiple sclerosis.
A safety evaluation of the drug for use against Crohn's disease and rheumatoid arthritis will be completed "in the coming weeks," the companies said in a joint statement.
They said that they completed a safety evaluation of the drug for use in multiple sclerosis patients in August.
Biogen, which is based in Cambridge, Mass., and Elan, which is based in Ireland, withdrew Tysabri from the market Feb. 28 after three patients developed a rare neurological disease.
-
Anthony H. Risser | neuroscience | neuropsychology | brain
- Business World: Biogen Idec, Elan, & Tysabri (natalizumab) And Ms
From the FDA: FOR IMMEDIATE RELEASE P06-25 February 16, 2006 Media Inquiries: Susan Cruzan, 301-827-6242 Consumer Inquiries: 888-INFO-FDA FDA Allows Clinical Studies of Tysabri (natalizumab) for Treatment of MS to Proceed The Food and...
- Business World: Biogen Idec, Elan, & Tysabri (natalizumab)
From the AP: Elan Shares Jump As Tysabri to Get Review By THE ASSOCIATED PRESS Published: November 18, 2005 Filed at 12:52 p.m. ET DUBLIN, Ireland (AP) -- Shares in Irish drug maker Elan Corp. PLC jumped Friday...
- Business World: Biogen Idec, Elan, & Tysabri (natalizumab) And Avonex (interferon Beta-1a)
From: RTE Ireland:Elan releases Tysabri trial figures July 19, 2005 11:09 Pharmaceutical company Elan has released figures showing that its suspended Tysabri drug improved the effectiveness of Biogen's Avonex in the treatment of multiple sclerosis....
- Business World: Biogen Idec, Elan, & Tysabri (natalizumab) (cont.)
Additional information in follow-up to this morning's Boston Globe report, from Bloomberg:Elan, Biogen Decline on Report of New Tysabri Illness June 2 (Bloomberg) -- Shares of Elan Corp. and Biogen Idec Inc. tumbled after a fourth possible case of...
- More M.s. Drug Woes: Avonex And 683699
Biogen and F.D.A. Issue Drug Warning By ANDREW POLLACK The New York Times Published: March 17, 2005 Biogen Idec's multiple sclerosis drug Avonex might cause severe liver damage in rare cases, the company and the Food and Drug Administration said...